SillaJen, a South Korean contract R&D services group, has signed a definitive agreement to acquire the private US oncolytic immunotherapy venture Jennerex in an all-cash transaction worth up to $150m including future milestone payments.
The deal builds on Busan-based SillaJen's position as the single largest shareholder in Jennerex and a working relationship between the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?